Clinical Trial Update: Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial [Phase 2]

View source ↗

Summary

Phase 2 study of M1774 (tuvusertib) in combination with avelumab for Merkel cell carcinoma; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• M1774 (tuvusertib) (tuvusertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING